Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
One weekly injection
This news comes as the national shortage of the popular glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) medications has improved, prompting the FDA to revisitand ultimately tightenits guidelines around the compounding of these drugs
Close provider communication ensures safe titration, side-effect monitoring, and efficacy tracking
The SURMOUNT-4 trial showed that stopping tirzepatide after 36 weeks of maximum-dose treatment led to approximately 14% weight regain, while continuing the medication produced an additional 5.5% loss
US$ 19.99
US$ 21.63
US$ 21.54
